Literature DB >> 23059546

Synthesis and pharmacological evaluation of pyrazolo[4,3-c]cinnoline derivatives as potential anti-inflammatory and antibacterial agents.

Rajiv Kumar Tonk1, Sandhya Bawa, Gita Chawla, Girdhar Singh Deora, Suresh Kumar, Vandana Rathore, Naveen Mulakayala, Azad Rajaram, Arunasree M Kalle, Obaid Afzal.   

Abstract

A series of pyrazolo[4,3-c]cinnoline derivatives was synthesized, characterized and evaluated for anti-inflammatory and antibacterial activity. Test compounds that exhibited good anti-inflammatory activity were further screened for their ulcerogenic and lipid peroxidation activity. Compounds 4d and 4l showed promising anti-inflammatory activity with reduced ulcerogenic and lipid peroxidation activity when compared to naproxen. Docking results of these two compounds with COX-2 (PDB ID: 1CX2) also exhibited a strong binding profile. Among the test derivatives, compound 4i displayed significant antibacterial property against gram-negative (Escherichia coli and Pseudomonas aeruginosa) and gram-positive (Staphylococcus aureus) bacteria. However, compound 4b emerged as the best dual anti-inflammatory-antibacterial agent in the present study.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23059546     DOI: 10.1016/j.ejmech.2012.08.045

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

1.  Synthesis, Anti-Inflammatory, and Ulcerogenicity Studies of Novel Substituted and Fused Pyrazolo[3,4-d]pyrimidin-4-ones.

Authors:  Alaa A El-Tombary
Journal:  Sci Pharm       Date:  2013-01-07

2.  Prenylated Flavonoids with Potential Antimicrobial Activity: Synthesis, Biological Activity, and In Silico Study.

Authors:  Mauricio Osorio; Marcela Carvajal; Alejandra Vergara; Estefania Butassi; Susana Zacchino; Carolina Mascayano; Margarita Montoya; Sophia Mejías; Marcelo Cortez-San Martín; Yesseny Vásquez-Martínez
Journal:  Int J Mol Sci       Date:  2021-05-22       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.